ramipril and potassium chloride

Pharmacodynamic interaction. Ramipril inhibits angiotensin-converting enzyme, reducing aldosterone secretion. Aldosterone normally promotes renal potassium excretion, so its suppression decreases potassium loss. Potassium chloride supplementation adds exogenous potassium, and the combination can overwhelm renal excretory capacity, leading to hyperkalaemia.

The combined effect can cause a rise in serum potassium concentration, potentially resulting in hyperkalaemia. Hyperkalaemia may manifest as muscle weakness, paraesthesia, and cardiac conduction abnormalities, including bradycardia, peaked T waves, and potentially life-threatening ventricular arrhythmias or asystole. Risk is increased in patients with renal impairment, diabetes, or concurrent use of other potassium-sparing agents.

Avoid routine co-prescription unless there is clear hypokalaemia and careful monitoring is possible. If used together, monitor serum potassium at baseline, within 5 to 7 days after starting or changing doses, and regularly thereafter, especially during intercurrent illness. Adjust the potassium chloride dose or discontinue if hyperkalaemia occurs. Check renal function periodically.

This interaction is well established in pharmacological literature and clinical practice guidelines. ACE inhibitors are known to cause potassium retention, and hyperkalaemia is a recognised adverse effect of their combination with potassium supplements. Monitoring recommendations are widely endorsed by cardiovascular and renal guidelines.